1. Sensitivity and Specificity of Urinary Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 for the Diagnosis of Renal Cell Carcinoma
   Jeremiah J. Morrissey et al, 2011, Am J Nephrol CrossRef
2. Hydrocarbons and Kidney Damage: Potential Use of Neutrophil Gelatinase-Associated Lipocalin and Sister Chromatide Exchange
   Antonio Lacquaniti et al, 2012, Am J Nephrol CrossRef
3. Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland
   Valeria Barresi et al, 2012, Virchows Arch CrossRef
4. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels
   Hugo You-Hsien Lin et al, 2013, The Kaohsiung Journal of Medical Sciences CrossRef
5. Neutrophil Gelatinase Associated Lipocalin is an Independent Predictor of Poor Prognosis in Cases of Papillary Renal Cell Carcinoma
   Mingxin Zhang et al, 2015, The Journal of Urology CrossRef
6. Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far
   Patricia A. Tang et al, 2011, Hematology/Oncology Clinics of North America CrossRef
7. null
   Valeria Cernaro et al, 2016 CrossRef
8. null
   Giuseppe Lippi et al, 2014 CrossRef
9. NGAL, biomarqueur de lésion rénale : point d’étape en 2012
   Amandine Gagneux-Brunon et al, 2012, Néphrologie & Thérapeutique CrossRef
10. Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma
    Valeria Barresi et al, 2011, Pathology - Research and Practice CrossRef
11. Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy
    Anastasia Asimakopoulou et al, 2016, Front. Physiol. CrossRef
12. Urinary NGAL and KIM-1: potential association with histopathologic features in patients with renal cell carcinoma
    Amjad Shalabi et al, 2013, World J Urol CrossRef
13. Lipocalin 2 performs contrasting, location-dependent roles in APCmin tumor initiation and progression
    P T Reilly et al, 2013, Oncogene CrossRef
14. Lipocalin 2: An Emerging Player in Iron Homeostasis and Inflammation.
    Xia Xiao et al, 2017, Annu Rev Nutr CrossRef
15. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors
    ANGELINA DI CARLO, 2013 CrossRef
16. Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage-specific prognostic factor?
    VALERIA BARRESI et al, 2010 CrossRef
17. Urinary Neutrophil Gelatinase Associated Lipocalin (NGAL) in Predicting Cisplatin-Induced Acute Kidney Injury
    Somayeh Sadat Shariatmaghani et al, 2019, Nephro-Urol Mon CrossRef
18. null
    Valeria Cernaro et al, 2015 CrossRef
19. The iron load of lipocalin-2 (LCN-2) defines its pro-tumour function in clear-cell renal cell carcinoma
    Claudia Rehwald et al, 2019, Br J Cancer CrossRef
20. Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types
    Sina Rahimi et al, 2020, Mol Biol Rep CrossRef
21. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer
    Saverio Candido et al, 2014, Oncotarget CrossRef
22. ARCHITECT® urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results)
    Hajer Ben Khadhra et al, 2020, Int Urol Nephrol CrossRef
23. Iron-Bound Lipocalin-2 Protects Renal Cell Carcinoma from Ferroptosis
    Julia K. Meier et al, 2021, Metabolites CrossRef